Published in Hematology Week, July 28th, 2008
"We at Calistoga are very pleased to be entering our first oncology trial. PI3K delta is a novel target in cancer, and we look forward to evaluating CAL-101 as a potential treatment to improve outcomes in patients with certain types of leukemias and lymphomas," said Albert Yu, M.D., Vice President, Clinical Affairs and Chief Medical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.